CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Lipum AB is developing a novel biological drug targeting chronic inflammatory diseases, aiming to provide an effective alternative for patients who do not respond to existing treatments. The project focuses on creating a drug that avoids suppressing the immune system while targeting conditions like Rheumatoid Arthritis…
Lipum AB has discovered a novel target protein for treatment of chronic inflammatory diseases.
We are now developing a biological drug that will inhibit the target molecule.
We propose an entirely new therapeutic mode of action as an alternative to current therapeutics that do not provide adequate response in as much as 1/3 of patients.
Our research and preclinical results indicate that our approach can be applied for treatment of an array of autoimmune and autoinflammatory conditions, and that…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
